Navigation Links
Duska Therapeutics Obtains Standard & Poor's Listing
Date:6/26/2008

LA JOLLA, Calif., June 26 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc. (OTC Bulletin Board: DSKA.OB) ("Duska" or the "Company") announced today that its company information is available via Standard & Poor's Corporation Records Listing Program. As part of the program, a full description of Duska Therapeutics is published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under the Blue Sky Laws. Standard Corporation Records is available in print, on CD-ROM, and via the Web at http://www.netadvantage.standardandpoors.com as well as through numerous electronic vendors.

The Duska Therapeutics corporate information now available through the Records Listing Program includes an in-depth description of the Company's business operations, share price, dividend history, shares outstanding, company's financial position, earnings, and full income statement and balance sheet.

Earlier this month Duska Therapeutics announced it has been granted an exclusive worldwide license from Duke University and Johns Hopkins University to develop and commercialize their rights to a portfolio of investigational cardiovascular drugs designed to correct nitric oxide and redox disequilibrium in the failing heart and cardiovascular system. The lead candidate is expected to enter Phase II clinical trials later this year.

About Duska Therapeutics, Inc.

Duska Therapeutics, Inc., in La Jolla, California, is a biotechnology company focused on the development of medical products based on adenosine triphosphate and nitric oxide. Duska owns or has exclusive licensing rights to proprietary medical products that are in various stages of development for the treatment and diagnosis of certain cardiac arrhythmias, treatment of heart failure, treatment of chronic obstructive pulmonary disorder, and improvement of
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... Corporation (Nasdaq: NEOG ) has been selected to ring the ... to celebrate Neogen,s 20th anniversary of being listed on the market. ... the countless many who have made Neogen,s success possible," said James ... long way in the 20 years since our initial offering, and ...
... ... Solutions , ... Indianapolis, IN (Vocus) November 12, 2009 -- DuPont and Dow AgroSciences, a wholly ... commercial cross-licensing agreement that will enable the two companies to deliver expanded herbicide-tolerant soybean options ...
... 12 Advanced Cell Technology,s (OTCBB: ACTC) Chief Scientific ... Plenary Lecture at the ,3rd International Conference on Cell ... on November 12, 2009. The Conference will focus ... will include sessions on ,Tissue Specific Stem Cell Therapy, ...
Cached Biology Technology:Neogen to Ring NASDAQ's Closing Bell 2DuPont, Dow AgroSciences Agree to Cross License Next-Generation Soybean Herbicide Tolerant Traits 2DuPont, Dow AgroSciences Agree to Cross License Next-Generation Soybean Herbicide Tolerant Traits 3DuPont, Dow AgroSciences Agree to Cross License Next-Generation Soybean Herbicide Tolerant Traits 4Advanced Cell Technology's Chief Scientific Officer, Robert Lanza, Opening Plenary Speaker at the '3rd International Conference on Cell Therapy' 2
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
(Date:12/10/2014)... 9, 2014  Wake Forest Baptist Medical Center today announced ... School of Medicine. Funding for this $50 million capital ... will be publicly launched next summer. ... former 60 series R.J. Reynolds Tobacco Company complex, adjacent ... begin immediately with plans to be ready to welcome ...
(Date:12/10/2014)... , December 9, 2014 ... BCARD Platform   ... meeting scheduling solutions for business-to-business (B2B) events, today ... leader in mobile near-field communication (NFC), Bluetooth low ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... have determined the molecular structure of a viral protein, ... virus 5 is part of a family of viruses ... to cold-like illness and is responsible for many hospitalizations ... Jan. 5 by the journal Nature. , Details of ...
... the detailed structure of an essential piece of the ... of human cancers. Understanding the physical shape of the ... it acts to immortalize cells ?and should help scientists ... lack of detailed structural information about the enzyme has ...
... from The Walter and Eliza Hall Institute, using a ... drives the formation of all breast tissue. This discovery ... tissue develops. The identification of the breast stem cell ... cancer develops and how rogue cells evade current therapies. ...
Cached Biology News:Scientists identify molecular structure of key viral protein 2Scientists identify molecular structure of key viral protein 3Scientists identify molecular structure of key viral protein 4Report lists top 20 most-vulnerable African carnivores 2Report lists top 20 most-vulnerable African carnivores 3Report lists top 20 most-vulnerable African carnivores 4Faults in newly discovered breast stem cells may lead to tumours 2
...
... of microplate readers combines reagent dispensing with ... affordable, easy-to-use platform for the complete range ... design and adaptability of the Infinite 200 ... a monochromator (M200) or filter (F200) system ...
Piperazine-N',N'-bis(2-ethanesulfonic acid), monosodium salt...
...
Biology Products: